Liquid discharges from patients undergoing 131I treatments

被引:20
作者
Barquero, R. [1 ]
Basurto, F. [2 ]
Nunez, C. [3 ]
Esteban, R. [4 ]
机构
[1] Hosp Univ Rio Hortega, Serv Radiofis & Protecc Radiol, E-47010 Valladolid, Spain
[2] Univ Valladolid, Dept Fis Teor Atom & Opt, E-47010 Valladolid, Spain
[3] Fdn Jimenez Diaz, Serv Radiofis & Protecc Radiol, E-82001 Madrid, Spain
[4] Hosp Clin Univ, Serv Radiol, E-47005 Valladolid, Spain
关键词
thyroid cancer; I-131; radioactive discharge; radioactive waste treatment system;
D O I
10.1016/j.jenvrad.2007.12.010
中图分类号
X [环境科学、安全科学];
学科分类号
08 ; 0830 ;
摘要
This work discusses the production and management of liquid radioactive wastes as excretas from patients undergoing therapy procedures with I-131 radiopharmaceuticals in Spain. The activity in the sewage has been estimated with and without waste radioactive decay tanks. Two common therapy procedures have been considered, the thyroid cancer (4.14 GBq administered per treatment), and the hyperthyroidism (414 MBq administered per treatment). The calculations were based on measurements of external exposure around the 244 hyperthyroidism patients and 23 thyroid cancer patients. The estimated direct activity discharged to the sewage for two thyroid carcinomas and three hyperthyroidisms was 14.57 GBq and 1.27 GBq, respectively, per week; the annual doses received by the most exposed individual (sewage worker) were 164 mu Sv and 13 mu Sv, respectively. General equations to calculate the activity as a function of the number of patient treated each week were also obtained. (c) 2007 Elsevier Ltd. All rights reserved.
引用
收藏
页码:1530 / 1534
页数:5
相关论文
共 11 条
[1]  
[Anonymous], SOURC EFF ION RAD
[2]  
[Anonymous], 1991, ANN ICRP, V60
[3]  
[Anonymous], [No title captured]
[4]   Liquid discharges from the use of radionuclides in medicine (diagnosis) [J].
Barquero, R. ;
Agulla, M. M. ;
Ruiz, A. .
JOURNAL OF ENVIRONMENTAL RADIOACTIVITY, 2008, 99 (10) :1535-1538
[5]  
Chapel M., 2002, GRUPO EFLUENTES FORO
[6]  
*IAEA, 2002, RS15 IAEA
[7]  
ICRP, 2004, ICRP PUBL, V94
[8]  
*US NUCL REG COMM, 1997, 839 US NUCL REG COMM
[9]  
Waters L.S., 2002, MCNPX MONTE CARLO N
[10]   Evaluation of the potential absorbed doses from patients based on whole-body 131I clearance in thyroid cancer therapy [J].
Willegaignon, J. ;
Stabin, Michael G. ;
Guimaraes, Maria I. C. ;
Malvestiti, Luiz F. ;
Sapienza, Marcelo T. ;
Maroni, Marilia ;
Sordi, Gian-Maria A. A. .
HEALTH PHYSICS, 2006, 91 (02) :123-127